A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival-Reference-Cited by-同舟云学术

A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival

Published:2021-05 Issue: Volume:104 Page:106555
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Garcia Jacqueline S.,Swords Ronan T.,Roboz Gail J.,Jacoby Meagan A.,Garcia-Manero Guillermo,Hong Wan-Jen^ORCID,Yang Xiaoqing,Zhou Ying,Platzbecker Uwe,Steensma David P.,Wolff Johannes E.,Fenaux Pierre

Funder

AbbVie Inc

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference46 articles.

1. Myelodysplastic syndromes: overview;Hasserjian,2017

2. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

3. Revised international prognostic scoring system for myelodysplastic syndromes;Greenberg;Blood,2012

4. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol.,2009

5. Treatment of MDS;Platzbecker;Blood,2019

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the management of higher-risk myelodysplastic syndromes: future prospects;Leukemia & Lymphoma;2024-05-07

2. Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives;Cancers;2024-04-15

3. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study;The Lancet Haematology;2024-03

4. Infectious Complications in Patients with Myelodysplastic Syndromes: A Report from the Düsseldorf MDS Registry;Cancers;2024-02-16

5. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax;Clinical Cancer Research;2024-02-01